CRA was retained on behalf of a pharmaceutical manufacturer to assess the commercial success of drugs indicated for the treatment of severe acne and the nexus between that success and the patents at issue. At issue was the combination use of active ingredients. CRA found commercial success and a nexus between that success and the patents at issue. Although the manufacturer provided patient coupons for copay relief, CRA found that pricing and marketing activity were not undue contributors to commercial success.
IP Literature Watch: March 2024
In this month’s IP Literature Watch we include an article analyzing four case studies of controversy over license design in open-source software and hardware...